TICKERNERD
Menu
MDLNHealthcare · Medical Instruments & Supplies

MDLN Stock Forecast: Medline, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$35
+1.28% on the day

The 27 Wall Street analysts covering Medline, Inc. hold a median 12-month price target of $45 — +29.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$46.1B
Ticker Nerd rank
19 / 100
Median analyst target
$45
Analysts covering
27
Total return, dividends reinvested
1W
−0.5%
1M
−10.5%
YTD
−17.4%
From high
−30.6%
From low
+6.5%
$33
$50
Range since 17 Dec 2025, adjusted closes · the dot is the last close
Ticker Nerd rank

MDLN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Medline, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
67
Issuance
62
Revisions
60
Quality
42
Value
36
Growth
32
Size
6
Momentum
1
Volatility
1

Accruals (67): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (1): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MDLN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MDLN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 17 Dec 2025Adjusted close, US dollars
$35$40$45$50$55Jan 26Apr 26Jul 26MDLNHigh $55Median $45Low $34

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says27 analysts
23 Buy4 Hold0 Sell
Low $34Median $45High $55

The green dot is the last close — the median target sits +29.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 10 moved it down.

DateFirmActionRatingTarget
12 Aug 2026JP MorganMaintainsOverweight$53 → $46
11 Aug 2026Tigress FinancialMaintainsBuy$62 → $55
11 Aug 2026Wells FargoMaintainsEqual-Weight$45 → $34
10 Aug 2026TD CowenMaintainsBuy$53 → $45
6 Aug 2026Evercore ISI GroupMaintainsOutperform$48 → $39
6 Aug 2026RBC CapitalMaintainsOutperform$53 → $46
6 Aug 2026StifelMaintainsBuy$50 → $45
6 Aug 2026Truist SecuritiesMaintainsBuy$56 → $47
31 July 2026BTIGReiteratesBuy$55
31 July 2026BTIGReiteratesBuy—
3 June 2026BairdMaintainsOutperform—
3 June 2026BairdMaintainsOutperform$57 → $45
1 June 2026BarclaysMaintainsOverweight$50 → $45
1 June 2026BarclaysMaintainsOverweight—
14 May 2026BNP ParibasMaintainsNeutral—
13 May 2026Tigress FinancialMaintainsBuy—
7 May 2026BernsteinMaintainsOutperform—
7 May 2026BTIGReiteratesBuy—
7 May 2026CitigroupMaintainsBuy—
11 Mar 2026CitigroupReinstatesBuy$60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MDLN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MDLN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.7%
Analysts raising
11
Analysts cutting
6
Fundamentals

Medline, Inc. (MDLN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
42.8×

Cheaper than 18% of US stocks

Price / sales
1.5×

Cheaper than 60% of US stocks

Price / book
2.6×

Cheaper than 39% of US stocks

EV / EBITDA
18.9×

Cheaper than 17% of US stocks

Growth & margins
Revenue growth (YoY)
11.6%

Higher than 56% of US stocks

Earnings growth (YoY)
−82.0%

Higher than 4% of US stocks

Gross margin
28.8%

Higher than 33% of US stocks

Operating margin
0.8%

Higher than 47% of US stocks

Net margin
2.3%

Higher than 53% of US stocks

Returns & dividend
Return on equity
4.9%

Higher than 53% of US stocks

Return on assets
2.5%

Higher than 62% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MDLN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
MDLNMedline, Inc.$46.1B
19
BDXBecton, Dickinson & Co.$52.9B
92
ALCAlcon AG$36.7B
69
RMDResMed, Inc.$33.8B
71
WSTWest Pharmaceutical Services, Inc.$25.4B
94
SOLVSolventum Corp.$15.5B
92
COOThe Cooper Cos., Inc.$14.9B
79

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Medline, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MDLN news & analysis

Kaplan Fox Announces a Securities Investigation into Medline Inc. (MDLN) - Investors Encouraged to Contact the Firm

Newsfile Corp · 24 Aug 2026negative

Kaplan Fox & Kilsheimer LLP announced it is investigating potential securities violations against Medline Inc. (NASDAQ: MDLN). The firm invited Medline investors who have suffered losses or who have relevant information to contact it regarding the investigation.

Why it matters — A securities investigation signals possible legal scrutiny over the company's conduct, which Medline watchers would want to monitor given its potential implications for the company.

MDLN INVESTIGATION: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm

GlobeNewsWire · 21 Aug 2026negative

The securities litigation law firm Kessler Topaz Meltzer & Check, LLP announced it is investigating potential federal securities law violations by Medline Inc. The firm is encouraging investors who purchased Medline Class A common stock and suffered significant financial losses to contact it.

Why it matters — A securities investigation signals potential legal or disclosure issues that could affect Medline investors holding its Class A common stock.

Kaplan Fox is Investigating Medline Inc. (MDLN) for Potential Violations of the Federal Securities Laws

Newsfile Corp · 19 Aug 2026negative

Kaplan Fox & Kilsheimer LLP is investigating potential violations of federal securities laws against Medline Inc. (NASDAQ: MDLN). The firm is inviting Medline investors who have suffered losses or who have information that could assist the investigation to contact it.

Why it matters — An active securities-law investigation into potential violations could bring regulatory or legal scrutiny to Medline, making it relevant for investors watching the company.

MDLN Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm

PRNewsWire · 18 Aug 2026negative

Kessler Topaz Meltzer & Check, LLP announced it is investigating potential violations of federal securities laws by Medline Inc. (NASDAQ: MDLN) on behalf of investors who purchased Medline Class A common stock and experienced significant financial losses. The firm is encouraging affected investors to contact it.

Why it matters — A securities law investigation into Medline signals potential legal and regulatory risk for the company that MDLN watchers should monitor.

FAQ

Frequently asked questions about MDLN stock

What is the MDLN stock price forecast for 2026-2027?

The 27 Wall Street analysts covering Medline, Inc. have a median 12-month price target of $45, with estimates ranging from $34 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MDLN stock a buy right now?

Of the 27 analysts covering Medline, Inc., 23 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Medline, Inc. 19 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MDLN?

As at 22 Aug 2026, Medline, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (67 of 100).

Will MDLN stock go up?

No one can know that. What the data says: the median 12-month target from 27 analysts implies +29.7% from the last close, and Ticker Nerd's factor model ranks Medline, Inc. 19 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MDLN stock forecast for 2030?

No analyst covering Medline, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDLN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $34 to $55 over the next 12 months.

What does Medline, Inc. do?

Medline Inc. is a healthcare company that provides medical-surgical products and supply chain solutions to healthcare providers.

What is the latest news on MDLN?

The most recent item we track (Newsfile Corp, 24 Aug 2026): "Kaplan Fox Announces a Securities Investigation into Medline Inc. (MDLN) - Investors Encouraged to Contact the Firm". Kaplan Fox & Kilsheimer LLP announced it is investigating potential securities violations against Medline Inc. (NASDAQ: MDLN). The firm invited Medline investors who have suffered losses or who have relevant information to contact it regarding the investigation.

Company

About Medline, Inc.

Medline Inc. is a healthcare company that provides medical-surgical products and supply chain solutions to healthcare providers. The company focuses on serving hospitals, surgery centers, physician offices, laboratories, and post-acute care facilities with a broad portfolio of consumable medical products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care items, wound care products, and lab and diagnostic supplies. Medline operates through two main segments: Medline Brand, which covers the procurement and manufacture of its own med-surg product lines, and Supply Chain Solutions, which delivers logistics, distribution, and inventory management services tailored to large healthcare systems. Headquartered in Northfield, Illinois, Medline positions itself as a key partner for healthcare institutions seeking to improve clinical, operational, and financial outcomes through reliable product availability, extensive branded offerings, and integrated supply chain capabilities in the medical-surgical space.

CEO Mr. James M. Boyle · 45,000 employees · United States · https://www.medline.com